

Empowerment Through Proven Neurotechnology

CONTROL
BIONICS®

LSI ASIA JULY 2026

JEREMY STEELE

CHIEF EXECUTIVE OFFICER

The Body Is Already Speaking - We Built the Ears

Surface Electromyography (sEMG) is a non-invasive technique used to measure and record the electrical activity of muscles through sensors on the skin.

Intent detection is the process of using muscle electrical signals to predict what movement a person wants to make before they actually make it.



Proven in the Hardest Clinical Use Case

25 Years of Clinical Validation

1,000s of Customers

9 Patents + Provisionals

FDA, TGA, CE Registered Devices



*Ryoka
Hatakeyama
Osaka, Japan
24 years old*

From Device Company to Neural Signal Platform



Peter Ford (Founder of Control Bionics, left) and Professor Stephen Hawking, 2002.



NeuroStrip Platform, 2026.


One Platform, Three Commercial Pillars



Assistive Communication
Our Proven Cash Engine.



NeuroTechSolutions *The Same Signal. A \$4.2B Market.*



Platform & Medical Technology
The Data Moat.
The Strategic Optionality.

Assistive Communication: Cash Engine

US\$1BN Global Market that is
growing >10% per annum*

Dedicated **HCPCS** funding code for
streamlined US reimbursement pathway

Funding provided in the biggest global
markets:

US, Australia, UK & Germany

* Based on a report by The Business Research Company January 2026 and Management estimates

**CONTROL
BIONICS®**



NeuroTech Solutions: Growth Engine

Elite Sport

Power athlete performance by integrating clinical-grade data in a wearable form factor.

>\$2BN Market Size*

Scale Opportunities

Consumerisation of sEMG for athletes


Rehabilitation

sEMG utilization within a rehabilitation setting improves patient outcomes and engagement.

>\$2.2BN Market Size*

Scale Opportunities

Innovative in clinic solution for insurance funded performance training



*Based on a Markets and Markets 2025 report on Sports Technology and a 2025 imarc report on Neurorehabilitation Devices

From the Pitch to the Clinic

Three Use Cases, One Platform

Performance Monitoring

Measure real-time neuromuscular load.



Athlete Profiling

Longitudinal signal and performance baselines.




Return-to-Play

Objective readiness metrics, not just guesswork.



Watch our NeuroTech in action



THIS IS

Platform & Medical Technology: Data, Apple BCI, Research

Proprietary Dataset

*25 years of unmatched
clinical-grade sEMG.*



Apple BCI

*Positioned at the centre of
the BCI ecosystem.*





Research Partnerships

*Academic validation.
Data that matters.*



Why now?

Control Bionics has 25 years of R&D in markets that are now primed for explosive growth.



Proven tech. Commercial Traction. Global Scaling

GLOBAL VALIDATION AND 25 YEAR OLD MOAT

GROWING CORE BUSINESS ACROSS MAJOR MARKETS

CLEAR PATH TO SCALE AND PROFITABILITY

TARGETING LARGE, UNMET MARKET NEEDS

HIGH MARGIN, MULTISTREAM REVENUE MODEL

CONTROL
BIONICS®

JEREMY STEELE

CHIEF EXECUTIVE OFFICER

JSTEELE@CONTROLBIONICS.COM

AUS:+61433 229 470

US:+1(855)831-7521

WWW.CONTROLBIONICS.COM